Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization

Neuropsychopharmacology

Volumn 30, Issue 5, 2005, Pages 871-879

  Panayi, Fany ^a,b   Colussi Mas, Joyce ^a,b   Lambás Señas, Laura ^a,b   Renaud, Bernard ^a,b   Scarna, Hélène ^a,b   Bérod, Anne ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Amphetamine; Induction; Locomotion; Neurotensin receptor antagonist; Sensitization; Ventral tegmental area

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; AMPHETAMINE; NEUROTENSIN; NEUROTENSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG SENSITIZATION; HISTOPATHOLOGY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; VENTRAL TEGMENTUM;

ADAMANTANE; AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; IMIDAZOLES; INJECTIONS, SUBCUTANEOUS; MALE; MICROINJECTIONS; MOTOR ACTIVITY; NEUROTENSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; VENTRAL TEGMENTAL AREA;

EID: 17644365416     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300638     Document Type: Article

References (65)

1. Alexander MJ, Leeman SE (1998). Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J Comp Neurol 402: 475-500.
2. Bauco P, Rompré PP (2003). Central neurotensin receptor activation produces differential behavioral responses in Fischer and Lewis rats. Psychopharmacology 168: 253-261.
3. Bayer VE, Towle AC, Pickel VM (1991). Ultrastructural localization of neurotensin-like immunoreactivity within dense core vesicles in perikarya, but not terminals, colocalizing tyrosine hydroxylase in the rat ventral tegmental area. J Comp Neurol 311: 179-196.
4. Beinfeld MC (2003). What we know and what we need to know about the role of endogenous CCK in psychostimulant sensitization. Life Sci 73: 643-654.
5. Bérod A, Rostène W (2002). Neurotensin: an endogenous psychostimulant? Curr Opin Pharmacol 2: 93-98.
6. Betancur C, Cabrera R, De Kloet ER, Pélaprat D, Rostène W (1998a). Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacology 19: 322-332.
7. Betancur C, Canton M, Burgos A, Labeeuw B, Gully D, Rostène W et al (1998b). Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain. Eur J Pharmacol 343: 67-77.
8. Binder EB, Gross RE, Nemeroff CB, Kilts CD (2002). Effects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats. Psychopharmacology 161: 288-295.
9. Binder EB, Kinkead B, Owens MJ, Kilts CD, Nemeroff CB (2001a). Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neurosci 21: 601-608.
10. Binder EB, Kinkead B, Owens MJ, Nemeroff CB (2001b). Neurotensin and dopamine interactions. Pharmacol Rev 53: 453-486.
11. Binder EB, Kinkead B, Owens MJ, Nemeroff CB (2004). Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs. Neuropsychopharmacology, print copy in press (originally published online July 27, 2004, at www.acn-p.org/citations/Npp07270403420/).
12. Boudin H, Pélaprat D, Rostène W, Beaudet A (1996). Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J Comp Neurol 373: 76-89.
13. Boudin H, Pélaprat D, Rostène W, Pickel VM, Beaudet A (1998). Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra. J Neurosci 18: 8473-8484.
14. Brun P, Leonetti M, Sotty F, Steinberg R, Soubrié P, Renaud B et al (2001). Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist. J Neurochem 77: 1542-1552.
15. Cador M, Bjijou Y, Stinus L (1995). Evidence for a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine. Neuroscience 65: 385-395.
16. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989). Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28: 653-661.
17. Casti P, Marchese G, Casu G, Ruiu S, Pani L (2004). Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. Neuropharmacology 47: 128-135.
18. Costa FG, Frussa-Filho R, Felicio LF (2001). The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. Eur J Pharmacol 428: 97-103.
19. During MJ, Bean AJ, Roth RH (1992). Effects of CNS stimulants on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from prefrontal cortex. Neurosci Lett 140: 129-133.
20. Ervin GN, Birkemo LS, Nemeroff CB, Prange Jr AJ (1981). Neurotensin blocks certain amphetamine-induced behaviors. Nature 291: 73-76.
21. Gruber SHM, Nomikos GG, Mathé A (2002). d-amphetamine-induced increase in neurotensin and neuropeptide Y outflow in the ventral striatum is mediated via stimulation of dopamine D1 and D2/3 receptors. J Neurosci Res 69: 133-139.
22. Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M et al (1997). Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther 280: 802-812.
23. Hertel P, Mathé JM, Nomikos GG, Iurlo M, Mathé AA, Svensson TH (1996). Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 72: 103-114.
24. Hooks MS, Jones GH, Liem BJ, Justice Jr JB (1992). Sensitization and individual differences to IP amphetamine, cocaine, or caffeine following repeated intracranial amphetamine infusions. Pharmacol Biochem Behav 43: 815-823.
25. Horger BA, Taylor JR, Elsworth JD, Roth RH (1994). Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization. Neuropsychopharmacology 11: 215-222.
26. Hösli E, Stauffer S, Hosli L (1995). Autoradiographic and electrophysiological evidence for the existence of neurotensin receptors on cultured astrocytes. Neuroscience 66: 627-633.
27. Jaworski JN, Vicentic A, Hunter RG, Kimmel HL, Kuhar MJ (2003). CART peptides are modulators of mesolimbic dopamine and psychostimulants. Life Sci 73: 741-747.
28. Kalivas PW, Burgess SK, Nemeroff CB, Prange Jr AJ (1983). Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience 8: 495-505.
29. Kalivas PW, Duffy P (1990). Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J Neurosci 10: 2940-2949.
30. Kalivas PW, Weber B (1988). Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine. J Pharmacol Exp Ther 245: 1095-1102.
31. Kinkead B, Nemeroff CB (2002). Neurotensin: an endogenous antipsychotic? Curr Opin Pharmacol 2: 99-103.
32. Laitinen K, Crawley JN, Mefford IN, de Witte P (1990). Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens. Brain Res 523: 342-346.
33. Leonetti M, Brun P, Sotty F, Steinberg R, Soubrie P, Bert L et al (2002). The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area. Naunyn-Schmiedeberg's Arch Pharmacol 365: 427-433.
34. Licata SC, Pierce RC (2003). The roles of calcium/calmodulin-dependent and Ras/mitogen-activated protein kinases in the development of psychostimulant-induced behavioral sensitization. J Neurochem 85: 14-22.
35. Magendzo K, Bustos G (2003). Expression of amphetamine-induced behavioral sensitization after short- and long-term withdrawal periods: participation of mu- and delta-opioid receptors. Neuropsychopharmacology 28: 468-477.
36. Mavridis M, Besson MJ (1999). Dopamine-opiate interaction in the regulation of neostriatal and pallidal neuronal activity as assessed by opioid precursor peptides and glutamate decarboxylase messenger RNA expression. Neuroscience 92: 945-966.
37. Nicot A, Rostène W, Bérod A (1995). Differential expression of neurotensin receptor mRNA in the dopaminergic cell groups of the rat diencephalon and mesencephalon. J Neurosci Res 40: 667-674.
38. Nouel D, Sarret P, Vincent JP, Mazella J, Beaudet A (1999). Pharmacological, molecular and functional characterization of glial neurotensin receptors. Neuroscience 94: 1189-1197.
39. Panayi F, Dorso E, Lambás-Señas L, Renaud B, Scarna H, Bérod A (2002). Chronic blockade of neurotensin receptors strongly reduces sensitized, but not acute, behavioral response to D-amphetamine. Neuropsychopharmacology 26: 64-74.
40. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
41. Perugini M, Vezina P (1994). Amphetamine administered to the ventral tegmental area sensitizes rats to the locomotor effects of nucleus accumbens amphetamine. J Pharmacol Exp Ther 270: 690-696.
42. Pierce RC, Bari AA (2001). The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci 12: 95-110.
43. Robinson TE, Becker JB, Presty SK (1982). Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences. Brain Res 253: 231-241.
44. Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentive sensitization theory of addiction. Brain Res Rev 18: 247-291.
45. Robledo P, Maldonado R, Koob GF (1993). Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-stimulation in the rat. Brain Res 622: 105-112.
46. Rompré P-P, Perron S (2000). Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization. Neuropharmacology 39: 1880-1892.
47. Rotzinger S, Bush DE, Vaccarino FJ (2002). Cholecystokinin modulation of mesolimbic dopamine function: regulation of motivated behaviour. Pharmacol Toxicol 91: 404-413.
48. Sarret P, Beaudet A, Vincent JP, Mazella J (1998). Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain. J Comp Neurol 394: 344-356.
49. Sarret P, Gendron L, Kilian P, Nguyen HM, Gallo-Payet N, Payet MD et al (2002). Pharmacology and functional properties of NTS2 neurotensin receptors in cerebellar granule cells. J Biol Chem 277: 36233-36243.
50. Sarret P, Perron A, Stroh T, Beaudet A (2003). Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system. J Comp Neurol 46: 520-538.
51. St-Gelais F, Legault M, Bourque MJ, Rompré PP, Trudeau LE (2004). Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. J Neurosci 24: 2566-2574.
52. Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS (2000). Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci 20: 3504-3511.
53. Sotty F, Soulière F, Brun P, Chouvet G, Steinberg R, Soubrié P et al (1998). Differential effects of neurotensin on dopamine release in the caudal and rostral nucleus accumbens: a combined in vivo electrochemical and electrophysiological study. Neuroscience 85: 1173-1182.
54. Steinberg R, Brun P, Fournier M, Souilhac J, Rodier D, Mons G et al (1994). SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience 59: 921-929.
55. Trudeau LE (2000). Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors. Neuroscience 97: 293-302.
56. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151: 99-120.
57. Vanderschuren LJ, Schmidt ED, De Vries TJ, Van Moorsel CA, Tilders FJ, Schoffelmeer AN (1999). A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats. J Neurosci 19: 9579-9586.
58. Vezina P (2004). Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 27: 827-839.
59. Walker N, Lépée-Lorgeoux I, Fournier J, Betancur C, Rostène W, Ferrara P et al (1998). Tissue distribution and cellular localization of the levocabastine-sensitive neurotensin receptor mRNA in adult rat brain. Brain Res Mol Brain Res 57: 193-200.
60. Werkman TR, Kruse CG, Nievelstein H, Long SK, Wadman WJ (2000). Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area. Neuroscience 95: 417-423.
61. Westerink BH, Tuntler J, Damsma G, Rollema H, de Vries JB (1987). The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn-Schmiedeberg's Arch Pharmacol 336: 502-527.
62. White FJ, Kalivas PW (1998). Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51: 141-153.
63. Wolf ME (1998). The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54: 679-720.
64. Woulfe J, Beaudet A (1992). Neurotensin terminals form synapses primarily with neurons lacking detectable tyrosine hydroxylase immunoreactivity in the rat substantia nigra and ventral tegmental area. J Comp Neurol 321: 163-176.
65. Zahm DS, Grosu S, Williams EA, Qin S, Bérod A (2001). Neurons of origin of the neurotensinergic plexus enmeshing the ventral tegmental area in rat: retrograde labeling and in situ hybridization combined. Neuroscience 104: 841-851.